戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                                             Eligible participants had information about self-reported dep
2                                                             Eligible participants were women aged 18 years or older with
3                                                             Eligible patients (aged >=18 years) had deleterious germline
4                                                             Eligible patients had previously untreated acute myeloid leuk
5                                                             Eligible patients were aged >=50 years.
6                                                             Eligible patients were those with operable, node-positive-or
7 e associated with 3.52 fewer expected kidney donors per 100 eligible deaths than non-Gulf States.
8                                              A total of 111 eligible patients (n(implants) = 501) were assessed.
9 17, and Dec 31, 2017, 55 enumeration area clusters had 1118 eligible index cases that led to 342 interventions covering 8
10                                                Among 39,226 eligible admissions, de-escalation occurred in 14,138 (36%),
11                                                    Of 1,239 eligible patients (61 +/- 18 years, 80% men), 1,072 (86%) had
12                                              There were 476 eligible PICU admissions, for whom 1,218 surveys were complet
13                                                  Of the 594 eligible eyes, the number with BCVA of 20/200 or worse at 2 y
14 n test outcome, giving an overall testing uptake among 6062 eligible children of 60.0%.
15  records of the remaining 109 clinics, we identified 13 657 eligible patients who were sent an introductory letter with 1
16                                                      Of 717 eligible relatives (598 first-degree and 119 second-degree re
17                                   Responses from 347 of 808 eligible first- and second-year adult nephrology fellows were
18  was created that matched one transplanted patient with all eligible control candidates.
19                    We analyzed antiretroviral therapy (ART)-eligible adults newly linking to care at 64 clinics in Zambia
20 ; median age 34 years [interquartile range 28-41]) were ART-eligible at enrollment.
21 h epithelioid sarcoma were enrolled in the study and deemed eligible for inclusion in this cohort.
22      By 2018, cumulative HCV treatment uptake in those ever eligible for treatment was 91% (336/371).
23      A detailed systematic search was performed to identify eligible randomized clinical trials (RCTs) reporting on the c
24 e 5,467 patients that were screened, 2,007 were molecularly eligible for entry into the trial, and 302 entered the trial
25 ieved SVR(12) , 10 had undetectable viral loads but are not eligible for SVR(12) , and 7 remain on treatment.
26  1 to December 31, 2016, and 8,172 of these underwent NSQIP-eligible surgical procedures.
27 Review, quality assessment, and risk assessment for bias of eligible publications were performed along recommended guidel
28 lteplase was an additional 1.7 (P<0.01), and the percent of eligible patients treated with alteplase increased by 8% (P=0
29                                         Low-income patients eligible for cost-sharing and premium subsidies in the Market
30 50% federal poverty level (FPL)] and middle-income patients eligible only for premium subsidies (251%-400% FPL) were comp
31 endon rupture at the participating centres were potentially eligible.
32                                         We identified three eligible trials and were able to obtain updated results for e
33 he addition of daratumumab (D) to RVd (D-RVd) in transplant-eligible NDMM patients was evaluated.
34 n models of acute ovarian failure risk were developed using eligible female US and Canadian participants in the Childhood
35 thens, Greece, between December 2014 and December 2017 were eligible for inclusion.
36                                           Of these, 32 were eligible to be included in the study.
37 4 livebirths and 43 spontaneous or elective abortions) were eligible for post-pregnancy viral load trajectory analyses (i
38 nd 168 (83 on afatinib + cetuximab and 85 on afatinib) were eligible.
39 12 years with grades II to IV steroid-refractory aGVHD were eligible to receive ruxolitinib orally, starting at 5 mg twic
40 >=0.9 as documented by computer tomography angiography were eligible for enrollment.
41                                            Instruments were eligible if they were originally developed to measure the con
42 articipants not on medication assisted treatment (MAT) were eligible.
43 d were on stable doses of anti-parkinsonian medication were eligible.
44       In the clinical study, 24 in vivo-in vitro pairs were eligible for further analysis, with 4 having been rejected as
45 2018, consecutive patients from the SwissTAVI Registry were eligible.
46 entified, and 68 papers reporting on 56 unique studies were eligible for inclusion.
47                                                 Trials were eligible for inclusion if published between 2008 and 2018 in
48 e children were estimated to suffer FA among those who were eligible but refused DBPCFC.
49                               Adults (aged >=18 years) were eligible for randomization on day 5 (+/-1 d) of microbiologic
50 ion to evaluate how WIC authorization affected sales of WIC-eligible foods in 8 DVS pilot stores, compared with 8 matched